Press Releases

Korber, the global leader in Manufacturing Execution Systems (MES) and integrated solutions, welcomes AGU Planungsgesellschaft fur Automatisierungs-, Gebaude- und Umwelttechnik mbH (AGU), a leading provider of middleware integrating a wide range of devices in laboratories, to its Korber Ecosystem Partner program as a “PAS-X MSI Plug & Produce” partner. AGU received the “Ready” level partner certificate for their data integration solution “Sm@rtLine

Veneno Technologies Co. Ltd. is pleased to announce that we have entered into a joint research agreement with Astellas Pharma Inc. Under the terms of the agreement, Veneno [https://veneno.jp/] will conduct a program to obtain functional peptides (DRPs) for G protein-coupled receptors (GPCRs) targeted by Astellas using our next-generation peptide discovery technology, the PERISS method (intra-periplasm secretion and selection). Work on this project is expected to begin during the 1st

Boehringer Ingelheim announced today the U.S. Centers for Medicare & Medicaid Services has issued a permanent J-code for SPEVIGO Injection, indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. According to the Healthcare Common Procedure Coding System (HCPCS), the J-code for SPEVIGO becomes effective as of today, April 1, 2023. "People living with GPP can experience unpredictable flares and are in need of timely access to novel treatment opt

Horus Pharma, an independent French laboratory specializing in ophthalmology, has taken a major step in its European expansion strategy with the opening of its new subsidiary. From its base in Stockholm, Horus Pharma Nordic will cover Sweden, Norway, Finland and Denmark, which together have 30 almost million inhabitants. Horus Pharma develops, patents and markets products and solutions for the treatment of eyes and eyelids without preservatives. The group focuses on using its medica

WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announces that it has added two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing at its Changzhou campus. The new additions further enhance the capability and capacity of WuXi TIDES. As an integral part of WuXi STA, WuXi TIDES is an end-to-end CRDMO platform for oligonucleotide, peptide, and related synthetic conjugates (“TIDES” drugs), si

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), taking place April 15-18, 2023 in Copenhagen, Denmark. Both presentations are from the company’s CORAL program, which is evaluating various self-amplifying mRNA (samRNA) vaccine candidates targeting Spike in addition to other viral genes o

AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced central Institutional Review Board (“IRB”) approval for the protocol of its Phase 2 study evaluating Ampligen® as a therapeutic for patients with post-COVID conditions (“AMP-518”). With this approval in hand, AIM is moving forward with the start-up process for the study’s

Design and optimization of the supply chain, packaging solutions for security and brand protection, cost-effective technologies towards continuous manufacturing, and transformation of pharmaceuticals with robotic solutions and AI are going to be discussed at the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2023). The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Geneva, Switzerland. The Pharmaceutical Manufacturing and

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it signed a service agreement with The Jikei University in Japan. Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan. In the feasibility study, scientists at the Milan site will focus on i

Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it has further expanded its relationship with Horus Pharma (Horus), one of the Company’s current distributors of ILUVIEN® in Europe. Alimera and Horus have agreed to expand their relationship beyond France, Belgium, Luxembourg and the Netherlands to increase the commercializat